Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance

被引:0
|
作者
Liping Yu
Andrew M. Petros
Arndt Schnuchel
Ping Zhong
Jean M. Severin
Karl Walter
Thomas F. Holzman
Stephen W. Fesik
机构
[1] Abbott Laboratories,Pharmaceutical Discovery Division
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The Erm family of methyltransferases is responsible for the development of resistance to the macrolide-lincosamide-streptogramin type B (MLS) antibiotics. These enzymes methylate an adenine of 23S ribosomal RNA that prevents the MLS antibiotics from binding to the ribosome and exhibiting their antibacterial activity. Here we describe the three-dimensional structure of an Erm family member, ErmAM, as determined by NMR spectroscopy. The catalytic domain of ErmAM is structurally similar to that found in other methyltransferases and consists of a seven-stranded β-sheet flanked by α-helices and a small two-stranded β-sheet. In contrast to the catalytic domain, the substrate binding domain is different from other methyltransferases and adopts a novel fold that consists of four α-helices.
引用
收藏
页码:483 / 489
页数:6
相关论文
共 50 条
  • [1] Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance
    Yu, LP
    Petros, AM
    Schnuchel, A
    Zhong, P
    Severin, JM
    Walter, K
    Holzman, TF
    Fesik, SW
    [J]. NATURE STRUCTURAL BIOLOGY, 1997, 4 (06) : 483 - 489
  • [3] Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance (vol 4, pg 483, 1997)
    Yu, LP
    Petros, AM
    SChnuchel, A
    Zhong, P
    Severin, JM
    Walter, K
    Holzman, TF
    Fesik, SW
    [J]. NATURE STRUCTURAL BIOLOGY, 1997, 4 (07): : 592 - 592
  • [4] MULTIPLICITY OF MACROLIDE-LINCOSAMIDE-STREPTOGRAMIN ANTIBIOTIC-RESISTANCE DETERMINANTS
    COURVALIN, P
    OUNISSI, H
    ARTHUR, M
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 : 91 - 100
  • [5] Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants
    Roberts, MC
    Sutcliffe, J
    Courvalin, P
    Jensen, LB
    Rood, J
    Seppala, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) : 2823 - 2830
  • [6] Heterogeneity of macrolide-lincosamide-streptogramin B resistance phenotypes in enterococci
    Min, YH
    Jeong, JH
    Choi, YJ
    Yun, HJ
    Lee, K
    Shim, MJ
    Kwak, JH
    Choi, EC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3415 - 3420
  • [7] Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes
    Roberts, Marilyn C.
    [J]. FEMS MICROBIOLOGY LETTERS, 2008, 282 (02) : 147 - 159
  • [8] Macrolide-Lincosamide-Streptogramin B Resistance Phenotypes in Staphylococcus Aureus
    Durmaz, Suleyman
    Kiraz, Asli
    Ozer, Turkan Toka
    Percin, Duygu
    [J]. EUROPEAN JOURNAL OF GENERAL MEDICINE, 2014, 11 (04): : 217 - 220
  • [9] Phenotypic Characterization of Macrolide-Lincosamide-Streptogramin B Resistance in Staphylococcus aureus
    Modukuru, Giridhar Kumar
    Surya, Pradeep Madala Sobhana
    Kakumanu, Vishnuvardhana Rao
    Yarava, Saritha
    [J]. JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2021, 15 (02): : 689 - 694
  • [10] Resistance to tetracycline, macrolide-lincosamide-streptogramin, trimethoprim, and sulfonamide drug classes
    Roberts, MC
    [J]. MOLECULAR BIOTECHNOLOGY, 2002, 20 (03) : 261 - 283